Longeveron (LGVN) Total Non-Current Liabilities (2022 - 2026)
Longeveron (LGVN) recorded quarterly Total Non-Current Liabilities of $838000.0 in Q1 2026, up 67.94% quarter-over-quarter from $499000.0 in Q4 2025, and down 13.25% on a YoY basis from $966000.0 in Q1 2025.
Longeveron (LGVN) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
Longeveron's Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $838000.0 for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 13.25% year-over-year to $838000.0; the TTM figure through Mar 2026 stood at $838000.0 (down 13.25% YoY), while the FY2025 annual figure was $499000.0, down 54.18% from the prior year.
- Total Non-Current Liabilities was $838000.0 for Q1 2026 at Longeveron, up from $499000.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $2.0 million in Q4 2022 to a low of $499000.0 in Q4 2025.
- Historically, Total Non-Current Liabilities has averaged $1.2 million across 5 years, with a median of $1.2 million in 2024.
- The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities slumped 54.18% in 2025, then dropped 13.25% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $2.0 million in 2022, then slipped by 29.05% to $1.4 million in 2023, then dropped by 24.79% to $1.1 million in 2024, then plunged by 54.18% to $499000.0 in 2025, then surged by 67.94% to $838000.0 in 2026.
- The last three Total Non-Current Liabilities figures came in at $838000.0 (Q1 2026), $499000.0 (Q4 2025), and $651000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 838,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 838,000.00 |
| Dec 31, 2025 | 499,000.00 |
| Sep 30, 2025 | 651,000.00 |
| Jun 30, 2025 | 809,000.00 |
| Mar 31, 2025 | 966,000.00 |
| Dec 31, 2024 | 1.09 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Jun 30, 2024 | 1.27 Mn |
| Mar 31, 2024 | 1.36 Mn |
| Dec 31, 2023 | 1.45 Mn |
| Sep 30, 2023 | 1.60 Mn |
| Jun 30, 2023 | 1.75 Mn |
| Dec 31, 2022 | 2.04 Mn |